ST. DAVID'S, Bermuda, Dec. 22 /PRNewswire-FirstCall/ -- Warner Chilcott Limited (Nasdaq: WCRX) today announced that its subsidiary Warner Chilcott Company, Inc. and Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (NYSE: BRL), have entered into a Settlement and License Agreement to resolve the pending patent litigation involving Warner Chilcott's oral contraceptive product, Femcon(R) Fe.
Under the terms of the agreement, Barr will have a license to launch a generic version of Femcon(R) Fe as early as July 1, 2012, approximately 7 years earlier than the expiration of the Warner Chilcott patent at issue in the litigation, or earlier in certain circumstances. Barr will pay Warner Chilcott a royalty on net sales of Barr's generic product. The parties will promptly file a dismissal without prejudice in the United States District Court for the District of New Jersey that will conclude this litigation.
About Warner Chilcott
Warner Chilcott is a specialty pharmaceutical company focused on developing, manufacturing, marketing and selling branded prescription pharmaceutical products in women's healthcare and dermatology in the U.S. WCRX-G.
Read more on www.warnerchilcott.com.
About Barr Pharmaceuticals, Inc.
Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Barr Group of companies markets more than 120 generic and 27 proprietary products in the U.S. and approximately 1,025 products globally outside of the U.S. For more information, visit www.barrlabs.com.
Warner Chilcott's Forward Looking Statements:
This press release contains forward-looking statements, including statements concerning our product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words 'may,' 'might,' 'will,' 'should,' 'estimate,' 'project,' 'plan,' 'anticipate,' 'expect,' intend,' 'outlook,' 'believe' and other similar expressions are intended to identify forward-looking statements.
